Study design
MIBC
HCRN GU 16–257 is phase 2, investigator-initiated, multicenter clinical trial. Cisplatin-eligible patients with MIBC enrolled at seven medical centers received treatment with gemcitabine, cisplatin, plus nivolumab (Fig. 